Summary
OCALA, Fla., March 02, 2026 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM)(AIM or the Company) today announced an agreement with the PPD clinical research business of Thermo Fisher Scientific to design AIMs anticipated Phase 3 clinical tr
Source: GlobeNewswire
Exclusive AI-Powered News Insights (For Members only)
Disclaimer:This content is AI-generated from various trusted sources and is intended for informational purposes only. While we strive for accuracy, we encourage you to verify details independently. Use the contact button to share feedback on any inaccuracies—your input helps us improve!
